CHST8 Antibody

What is CHST8 and why is it studied in research?

CHST8 (carbohydrate sulfotransferase 8) is a 424 amino acid protein with a molecular mass of 48.8 kDa that catalyzes the transfer of sulfate to position 4 of non-reducing N-acetylgalactosamine (GalNAc) residues in both N-glycans and O-glycans . This enzyme is localized in the Golgi apparatus and shows high expression in the pituitary gland. CHST8 has gained significant research interest due to its role in immune checkpoint blockade (ICB) responses in cancer therapy, where its expression levels have been shown to affect T cell activation and tumor microenvironment composition . The protein is also known by several synonyms including GalNAc-4-O-sulfotransferase 1, N-acetylgalactosamine-4-O-sulfotransferase 1, galNAc4ST-1, and GALNAC-4-ST1 .

What are the common applications for CHST8 antibodies in research?

CHST8 antibodies are utilized across multiple experimental applications, with varying frequency and success rates as shown in the table below:

Researchers should note that Western Blot represents the cornerstone of most manufacturers' validation protocols, while applications like protein capture from cell lysates are rarely tested by manufacturers .

What are the different types of CHST8 antibodies available and how do they compare?

Three main types of CHST8 antibodies are available for research:

• Polyclonal antibodies: Derived from immune cells of immunized animals, these recognize multiple epitopes on CHST8. While offering high sensitivity, they may have batch-to-batch variability and potentially higher cross-reactivity .

• Monoclonal antibodies: Produced from a single B-cell clone, these target a specific epitope on CHST8. They provide consistent results between batches but may have lower sensitivity than polyclonals .

• Recombinant antibodies: Generated through synthetic gene expression systems, these offer the highest consistency and specificity. Recent third-party validation studies have shown that recombinant antibodies generally outperform both polyclonal and monoclonal antibodies, with approximately two-thirds of traditional antibodies failing to recognize their target in recommended applications .

When selecting an antibody, researchers should consider the validation data provided by manufacturers or independent sources, as well as the specific experimental requirements.

Why is there a discrepancy between the calculated and observed molecular weight of CHST8 in Western blots?

While the calculated molecular weight of human CHST8 is 48.8 kDa (for the 424 amino acid canonical form), researchers frequently observe CHST8 at approximately 30-35 kDa in Western blot experiments . This discrepancy may be attributed to several factors:

• Post-translational modifications: CHST8 undergoes glycosylation and potentially other modifications that can alter its migration pattern .

• Protein isoforms: Alternative splicing may generate shorter isoforms of CHST8.

• Proteolytic processing: The protein may undergo specific cleavage during sample preparation or in vivo.

• Antibody specificity issues: Some antibodies may detect fragments or cross-react with related proteins.

When validating a new CHST8 antibody, researchers should compare their observed band pattern with published literature and consider using knockout/knockdown controls to confirm specificity.

How can researchers validate the specificity of CHST8 antibodies in their experiments?

Rigorous validation of CHST8 antibodies is essential for experimental reproducibility. A comprehensive validation approach should include:

• Positive and negative controls:

  • Use cell lines known to express high levels of CHST8 mRNA as positive controls

  • Utilize CRISPR-Cas9 knockout models as definitive negative controls

  • Include siRNA or shRNA knockdown samples as complementary negative controls

• Multiple detection methods:

  • Validate across different applications (WB, IF, IHC) if the antibody will be used in multiple contexts

  • Compare results between different antibodies targeting distinct epitopes of CHST8

• Specificity testing:

  • Perform peptide competition assays

  • Test reactivity in samples from different species if cross-reactivity is claimed (common orthologs include mouse, rat, bovine, frog, chimpanzee and chicken)

• Technical validation:

  • Ensure appropriate positive signals in expected molecular weight range (both the calculated 48.8 kDa and observed 30-35 kDa ranges)

  • Verify subcellular localization is consistent with Golgi apparatus distribution

Recent studies have highlighted the importance of third-party validation, as up to two-thirds of commercially available antibodies may fail to recognize their targets as advertised, contributing to the reproducibility crisis in research .

What are common pitfalls when using CHST8 antibodies and how can they be avoided?

Several challenges may arise when working with CHST8 antibodies:

• Non-specific binding: Despite manufacturer claims, many antibodies exhibit cross-reactivity with non-target proteins. This is particularly problematic as antibodies that failed specificity tests have been used in hundreds of published studies . To mitigate this issue:

  • Always include appropriate negative controls (knockout/knockdown)

  • Optimize blocking conditions to reduce background

  • Consider using secondary-only controls to identify non-specific binding of detection antibodies

• Inconsistent performance between applications: An antibody validated for Western blot may not perform well in immunofluorescence or immunohistochemistry. Researchers should:

  • Validate antibodies specifically for each intended application

  • Not assume cross-application performance without validation

  • Consider application-specific antibodies when possible

• Batch-to-batch variability: Particularly with polyclonal antibodies, there can be significant performance differences between lots. Best practices include:

  • Purchasing sufficient quantity of a validated lot for entire project needs

  • Re-validating new lots against previous standards

  • Considering recombinant antibodies for long-term projects requiring consistency

• Inappropriate storage and handling: To maintain antibody function:

  • Follow manufacturer's storage recommendations (typically -20°C with 50% glycerol)

  • Avoid repeated freeze-thaw cycles

  • Consider aliquoting antibodies upon receipt

How are CHST8 antibodies being used to study cancer immunotherapy response mechanisms?

Recent genome-wide association studies have identified CHST8 as a significant factor in immune checkpoint blockade (ICB) therapy responses. Researchers are utilizing CHST8 antibodies to explore:

• Genetic variant effects: The rs111308825 locus in the CHST8 enhancer region affects KLF2 binding, resulting in differential CHST8 expression. Antibodies are used to quantify protein levels in patients with different genetic variants to correlate with ICB response .

• T cell activation mechanisms: Studies have shown that breast cancer cells expressing CHST8 suppress T cell activation. Antibodies help visualize and quantify CHST8 in tumor samples and immune cells to map this suppressive pathway .

• Tumor microenvironment analysis: CHST8 activity appears to influence M2-like macrophage enrichment in the tumor microenvironment through sulfation of PD-L1 and its homologs. Immunohistochemistry with CHST8 antibodies helps characterize this microenvironment .

• Biomarker development: Low-CHST8 tumors demonstrate better ICB response, positioning CHST8 as a potential predictive biomarker. Immunodetection of CHST8 in patient samples is being explored for clinical applications .

These applications require highly specific antibodies validated for the intended techniques to ensure reliable results that can inform clinical decision-making.

What methods can be used to study CHST8 enzyme activity beyond expression level analysis?

While antibodies primarily detect CHST8 protein expression, researchers interested in enzyme activity require complementary approaches:

• Sulfation assays: These directly measure the transfer of sulfate from 3'-phosphoadenosine-5'-phosphosulfate (PAPS) to GalNAc residues. Methods include:

  • Radioactive assays using [35S]PAPS

  • HPLC-based detection of sulfated glycans

  • Mass spectrometry analysis of sulfated products

• Glycan analysis in CHST8 manipulated systems:

  • Generate CHST8 overexpression or knockout models

  • Use antibodies to confirm expression changes

  • Analyze glycan sulfation patterns using mass spectrometry or lectin arrays

• Proximity labeling with CHST8 antibodies:

  • Employ techniques like BioID or APEX2 to identify proteins in proximity to CHST8

  • Use antibodies for pulldown of biotinylated proximity partners

  • Analyze the interactome to understand functional complexes

• Combined immunoprecipitation and activity assays:

  • Immunoprecipitate CHST8 using validated antibodies

  • Perform in vitro sulfation assays with the immunoprecipitated enzyme

  • Analyze factors affecting enzymatic activity

These approaches provide a more comprehensive understanding of CHST8 function beyond simple expression analysis.

How can multiplexed antibody-based approaches be optimized for studying CHST8 in complex systems?

As research moves toward understanding CHST8 in the context of complex biological systems, multiplexed approaches offer significant advantages:

• Multi-color immunofluorescence optimization:

  • Carefully select CHST8 antibodies raised in different host species than other target antibodies

  • Validate absence of cross-reactivity between secondary antibodies

  • Use appropriate controls including single-antibody stains

  • Consider spectral unmixing for closely overlapping fluorophores

• Mass cytometry (CyTOF) applications:

  • Metal-conjugated CHST8 antibodies can be combined with dozens of other markers

  • Requires thorough antibody validation and titration

  • Enables single-cell analysis of CHST8 in heterogeneous populations

  • Can correlate CHST8 expression with cell type and functional markers

• Spatial transcriptomics integration:

  • Combine CHST8 antibody staining with spatial transcriptomics

  • Map protein expression against mRNA expression patterns

  • Identify potential post-transcriptional regulation mechanisms

  • Requires careful optimization of fixation and permeabilization protocols

• Single-cell proteogenomics:

  • Integrate antibody-based detection with genomic analysis at single-cell level

  • Correlate CHST8 protein levels with genetic variants like rs111308825

  • Understand cell-specific regulation mechanisms

  • Requires highly specific antibodies validated for single-cell applications

What are the considerations for developing next-generation CHST8 antibodies with improved specificity and versatility?

The development of more reliable CHST8 antibodies remains a priority given the high failure rate of existing commercial antibodies. Key considerations include:

• Recombinant antibody technology:

  • Develop synthetic antibodies with precisely defined binding properties

  • Engineer for specific applications (WB, IF, IP) with optimized performance

  • Create renewable resources that eliminate batch-to-batch variability

  • Third-party testing has shown recombinant antibodies generally outperform traditional types

• Epitope selection strategies:

  • Target unique regions of CHST8 to minimize cross-reactivity

  • Avoid heavily glycosylated domains that may interfere with epitope recognition

  • Consider developing antibodies against both N-terminal and C-terminal regions

  • Create phospho-specific antibodies if regulatory phosphorylation sites are identified

• Validation standardization:

  • Implement rigorous validation protocols using CRISPR knockout controls

  • Establish minimum performance criteria across multiple applications

  • Create centralized validation resources and repositories for antibody performance data

  • Consider international standards for antibody validation reporting

• Functional antibody development:

  • Design antibodies that specifically inhibit CHST8 enzymatic activity

  • Develop conformation-specific antibodies that recognize active versus inactive states

  • Create antibodies compatible with live-cell imaging applications

  • Engineer bifunctional antibodies for targeted degradation or localization studies

These advanced approaches will support more reliable and informative CHST8 research while addressing the broader challenges of antibody reproducibility in the scientific community.